These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 24703906)

  • 1. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.
    Yamazaki H; Suzuki M; Otsuki A; Shimizu R; Bresnick EH; Engel JD; Yamamoto M
    Cancer Cell; 2014 Apr; 25(4):415-27. PubMed ID: 24703906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two effects of GATA2 enhancer repositioning by 3q chromosomal rearrangements.
    Suzuki M; Katayama S; Yamamoto M
    IUBMB Life; 2020 Jan; 72(1):159-169. PubMed ID: 31820561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chromosomal rearrangements between 3q21 and 3q26 induce leukemogenesis by misdirecting both EVI1 and GATA2 genes].
    Suzuki M
    Rinsho Ketsueki; 2017; 58(7):806-812. PubMed ID: 28781278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
    Katayama S; Suzuki M; Yamaoka A; Keleku-Lukwete N; Katsuoka F; Otsuki A; Kure S; Engel JD; Yamamoto M
    Blood; 2017 Aug; 130(7):908-919. PubMed ID: 28630119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
    Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.
    Gröschel S; Sanders MA; Hoogenboezem R; de Wit E; Bouwman BAM; Erpelinck C; van der Velden VHJ; Havermans M; Avellino R; van Lom K; Rombouts EJ; van Duin M; Döhner K; Beverloo HB; Bradner JE; Döhner H; Löwenberg B; Valk PJM; Bindels EMJ; de Laat W; Delwel R
    Cell; 2014 Apr; 157(2):369-381. PubMed ID: 24703711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic dark matter sheds light on EVI1-driven leukemia.
    Koche RP; Armstrong SA
    Cancer Cell; 2014 Apr; 25(4):407-8. PubMed ID: 24735919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
    Ottema S; Mulet-Lazaro R; Beverloo HB; Erpelinck C; van Herk S; van der Helm R; Havermans M; Grob T; Valk PJM; Bindels E; Haferlach T; Haferlach C; Smeenk L; Delwel R
    Blood; 2020 Jul; 136(2):224-234. PubMed ID: 32219447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26).
    Suzukawa K; Parganas E; Gajjar A; Abe T; Takahashi S; Tani K; Asano S; Asou H; Kamada N; Yokota J
    Blood; 1994 Oct; 84(8):2681-8. PubMed ID: 7919381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
    Kiehlmeier S; Rafiee MR; Bakr A; Mika J; Kruse S; Müller J; Schweiggert S; Herrmann C; Sigismondo G; Schmezer P; Krijgsveld J; Gröschel S
    Leukemia; 2021 Nov; 35(11):3127-3138. PubMed ID: 33911178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
    Wang HY; Rashidi HH
    Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.
    Tanaka A; Nakano TA; Nomura M; Yamazaki H; Bewersdorf JP; Mulet-Lazaro R; Hogg S; Liu B; Penson A; Yokoyama A; Zang W; Havermans M; Koizumi M; Hayashi Y; Cho H; Kanai A; Lee SC; Xiao M; Koike Y; Zhang Y; Fukumoto M; Aoyama Y; Konuma T; Kunimoto H; Inaba T; Nakajima H; Honda H; Kawamoto H; Delwel R; Abdel-Wahab O; Inoue D
    Blood; 2022 Aug; 140(8):875-888. PubMed ID: 35709354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
    Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
    Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional cytogenetics and breakpoint distribution by fluorescent in situ hybridization in patients with malignant hemopathies associated with inv(3)(q21;q26) and t(3;3)(q21;q26).
    De Braekeleer E; Douet-Guilbert N; Basinko A; Bovo C; Guéganic N; Le Bris MJ; Morel F; De Braekeleer M
    Anticancer Res; 2011 Oct; 31(10):3441-8. PubMed ID: 21965759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis.
    Yamaoka A; Suzuki M; Katayama S; Orihara D; Engel JD; Yamamoto M
    Blood Adv; 2020 Apr; 4(8):1722-1736. PubMed ID: 32330245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
    Fears S; Mathieu C; Zeleznik-Le N; Huang S; Rowley JD; Nucifora G
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1642-7. PubMed ID: 8643684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia.
    Smeenk L; Ottema S; Mulet-Lazaro R; Ebert A; Havermans M; Varea AA; Fellner M; Pastoors D; van Herk S; Erpelinck-Verschueren C; Grob T; Hoogenboezem RM; Kavelaars FG; Matson DR; Bresnick EH; Bindels EM; Kentsis A; Zuber J; Delwel R
    Cancer Discov; 2021 Nov; 11(11):2868-2883. PubMed ID: 33980539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of SF3B1 mutations in EVI1-rearranged myeloid neoplasms].
    Tanaka A
    Rinsho Ketsueki; 2023; 64(10):1258-1265. PubMed ID: 37914237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
    J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression.
    Ohyashiki JH; Ohyashiki K; Shimamoto T; Kawakubo K; Fujimura T; Nakazawa S; Toyama K
    Blood; 1995 Jun; 85(12):3713-8. PubMed ID: 7780155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.